NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin

Buyer: NHS England

Deadline

Not available — this notice may describe a possible future opportunity.

Region

Not specified

Value

£25,881,000

Type

Award,contract

SME fit

—

Duration

—

Description

Project title: NHS National Framework for Transition Products (Apremilast, Pazopanib and Dapagliflozin) commencing 1st February 2026 Offer reference number: CM/TNS/25/5735 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/25/5735 Apremilast, Pazopanib and Dapagliflozin Lot 1 DLN/DNW: 01/02/2026 to 31/01/2027 (12 months) Lot 2 DLS/DNE: 01/02/2026 to 31/01/2027 (12 months) Lot 3 DCE/DSW: 01/02/2026 to 30/09/2027 (20 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Awarded to

ZENTIVA PHARMA UK LIMITED £25,881,000 THORNTON & ROSS LIMITED £25,881,000 Teva UK Limited £25,881,000 GLENMARK PHARMACEUTICALS EUROPE LIMITED £25,881,000 Farmak Pharmaceuticals UK Ltd £25,881,000 DR REDDY'S LABORATORIES (UK) LIMITED £25,881,000 CELIX PHARMA LTD £25,881,000 ACCORD-UK LTD £25,881,000

Quick actions

View original notice

Key details

CPV category: —
Procurement method: Open procedure
Published: 26 Nov 2025 15:36
VCSE suitable: —

Reference

OCID: ocds-h6vhtk-05936a
Notice ID: C386886
In our database since: 18 Aug 2026